This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

# Synthesis of Novel DNA Analoues Containing Aminomethylphosphonate Internucleoside Linkages

V. A. Efimov<sup>a</sup>; M. V. Choob<sup>a</sup>; A. L. Kalinkina<sup>a</sup>; O. G. Chakhmakkcheva<sup>a</sup>

<sup>a</sup> Shemyakin and Ovchinnikov Institute of Bioorganic Chemistyr, Russian Academy of Sciences, Moscow, Russia

To cite this Article Efimov, V. A., Choob, M. V., Kalinkina, A. L. and Chakhmakkcheva, O. G.(1997) 'Synthesis of Novel DNA Analoues Containing Aminomethylphosphonate Internucleoside Linkages', Nucleosides, Nucleotides and Nucleic Acids, 16: 7, 1475 - 1480

To link to this Article: DOI: 10.1080/07328319708006210 URL: http://dx.doi.org/10.1080/07328319708006210

### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF NOVEL DNA ANALOGUES CONTAINING AMINOMETHYLPHOSPHONATE INTERNUCLEOSIDE LINKAGES

V.A.Efimov\*, M.V.Choob, A.L.Kalinkina and O.G.Chakhmakhcheva

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul.Miklukho-Maklaya 16/10, Moscow 117871, Russia

**ABSTRACT**: Modified oligodeoxyribonucleotides with aminomethylphosphonate bonds between nucleoside residues were prepared and investigated for their hybridisation properties toward DNA and RNA.

Last years an impressive number of oligonucleotide analogues has been developed as potential therapeutics for the antisense and antigene approach<sup>1</sup>. Recently, we reported the preparation of a DNA analogue, in which the natural phosphodiester bonds have been replaced by the carboxamidophosphate linkages<sup>2</sup> and a novel phosphonate PNA analogues containing N-2-(hydroxyethyl)aminomethyl<sup>3</sup>, or N-2-(aminoethyl)aminomethyl phosphonate<sup>4</sup> backbone. We now report the preparation of a set of new aminomethyl-phosphonate DNA analogues (I-III) containing -N(R)-CH<sub>2</sub>-P(O<sub>2</sub>)<sup>2</sup>-O- internucleoside linkages.

1476 EFIMOV ET AL.

### Reagents and conditions:

- (a) CH<sub>2</sub>O (1.2eq.) in CH<sub>3</sub>CN, 15 min;
- (b) diphenyl phosphite (1 eq.) in toluene, 75°C,1-2 h;
- (c) (Acyl)<sub>2</sub>O (3 eq.) / Melm (3 eq.) in toluene, 1-2 h;
- (d) DBU (0.5 M) in CH<sub>3</sub>CN H<sub>2</sub>O (9.5 : 0.5, v/v), 15-30 min;
- (e) R'-OH (1.25 eq.), TPSNT (1.5 eq.) in acetonitrile pyridine (4:1,v/v), 10 min;
- (f) DBU (0.5 M) in  $CH_3CN H_2O$  (9.5 : 0.5, v/v), 15-30 min.

Scheme 1

Procedures to obtain corresponding thymine and cytosine monomeric units having the combination of blocking groups compatible with the DNA phosphotriester synthesis has been developed. As a starting compounds for the synthesis of monomers (1) and (2), 5'-or 3'-aminonucleosides with the dimethoxytrityl protective group on a OH-function were

 $R = -CF_{3_1} - CH_{3_2}$  or  $-CH_2CH_2CH_3$ 

### Reagents and conditions:

- (a) RuCl<sub>3</sub>.H<sub>2</sub>O (cat),  $K_2S_2O_8$  (4.5 eq.), 1 M KOH, 6 h<sup>7</sup>;
- (b) (PhO)<sub>2</sub>PO-CH<sub>2</sub>-NH<sub>2</sub> (1.1 eq.), MeIm (1.5 eq.), BOP (1.1 eq.), in CH<sub>2</sub>Cl<sub>2</sub>, 10 min;
- (c) DBU (0.5 M), in CH<sub>3</sub>CN H<sub>2</sub>O (9.5 : 0.5, v/v), 15 min;
- (d) R'OH (1.25 eq.), TPSNT (1.5 eq.) in CH<sub>3</sub>CN pyridine (4:1, v/v), 5 min;
- (e) DBU (0.5 M) in CH<sub>3</sub>CN H<sub>2</sub>O (9.5 : 0.5, v/v), 30 min.

Scheme 2

chosen. Using the same chemistry as for the synthesis of phosphono-PNA analogues<sup>3,4</sup>, we prepared several variants of the nucleoside aminomethylphosphonates (1,2) having different N-acyl blocking groups for the secondary amino function (SCHEME 1). Easy removable trifluoroacetyl blocking group was used to obtain the zwitterionic DNA analogues (Ia) and (IIa), whereas acetyl and butyryl N-blocking groups were used to prepare corresponding anionic N-acylaminomethylphosphonate analogues (Ib, IIb), in which N-acyl group is external to the internucleoside linkage. For comparison with analogues (Ib, and IIb), the preparation of the deoxyribonucleoside derivative of the type (3) for the synthesis of oligomers (III) with carboxamidomethyl phosphonate linkers, in which amide bond is a part of the internucleoside linkage, was realised by the chain of reactions shown in SCHEME 2. All monomers bear 1-oxido-4-methoxy-2-picolyl phosphonate protecting group, which could enhance the rate of the phosphonate function esterification as an effective O-nucleophilic catalyst<sup>5,6</sup>.

1478 EFIMOV ET AL.

TABLE. One elongation cycle for the solid phase phosphotriester synthesis of aminomethylphosphonate DNA analogues (I-III)

Step	Solvents and reagents*	Time(min)
. Detritylation	3%DCA in dichloromethane	1.5
2. Wash	Acetonitrile	3.0
Coupling	0.08 M P-component; 0.25 M TPSNT in	
	acetonitrile - pyridine (4:1, v/v)	5-10
. Wash	Acetonitrile	0.5
Capping	Ac <sub>2</sub> O - MeIm - collidine - THF	
	(1:1.6:1:16.4, v/v/v/v)	1.0
. Wash	Acetonitrile	2.0

<sup>\*</sup>Reactions were performed using 30 mg of CPG support (1 jumol of the first nucleoside).





FIG 1. Analysis of the crude modified (T\*)<sub>15</sub> oligomer of the type (III) by anion-exchange FPLC on Pharmacia Mono-Q column with a flow rate 0.5 ml/min using a gradient of NaCl in 0.01 M NaOH (pH=12).



**FIG.2.** The melting temperature curves [in 0.02 M Tris-HCl (pH=7.5) / 0.2 M NaCl] of the hybrides consisting of an oligo- $T^*_{15}$  analogue and its unmodified complementary ribo- $A_{15}$  target [A- analogue (IIa); B - analogue (IIb) and C - analogue (III)]; that of two unmodified complementary oligonucleotides (D) and single-stranded  $A_{15}$  oligomer (E).

The monomers obtained were applied for the automated solid phase synthesis of the aminomethylphosphonate linked thymidine and deoxycytidine containing oligonucleotide analogues. As a support, we used long chain alkylamine CPG functionalized with 5'-(DMTr)T-3'-O-succinate for the derivatives (1) and with 5'-O-succinyl-T(DMTr)-3' for the derivatives (2) and (3). The conditions for one step of chain elongation are summarised in the Table. The coupling efficiency of each elongation cycle was 95-97% depending on the monomer used, as gauged spectrophoto-metrically by releasing dimethoxytrityl cation. After the completion of the synthesis and the removal of the terminal trityl group, the support was treated with triethylammonium thiophenolate to remove P-protecting group<sup>5</sup> and then with concentrated ammonia (20°C, 16 h). The deprotected oligomers were isolated by preparative denaturing PAGE, or by anion-exchange FPLC (FIG.1) and desalted.

The preliminary investigations of these modified oligomers properties revealed that they are more stable to the exonuclease degradation than oligonucleotides bearing phosphodiester bonds. The oligomers with carboxamidomethyl phosphonate ester linkages (III) hybridized to DNA and RNA similarly to unmodified oligonucleotides and significantly better than modified oligomers of types (I) and (II) (FIG.2).

1480 EFIMOV ET AL.

### REFERENCES

- 1. De Mesmaeker, A.; Haner, R.; Martin, P.; Moser, H. Acc. ('hem. Res. 1995, 28, 366.
- 2. Filippov, D.; Meeuwenoord, N.; van der Marel, G.; Efimov, V.; Kuyl-Yeheskiely, E.; van Boom, J. Syn. Lett. 1996, 769.
- 3. van der Laan, A.; Strömberg, R.; van Boom, J.; Kuyl-Yeheskiely, E.; Efimov, V.; Chakhmakhcheva, O. *Tetrahedron Lett.*, **1996**, in press
- 4. Efimov, V.; Choob, M.; Kalinkina, A.; Chakhmakhcheva, O.; Stromberg, R.; van der Laan, A.; Meeuwenoord, N.; Kuyl-Yeheskiely, E.; van Boom, J. *Collect. Czech. Chem. Commun.* 1996, 61, s262.
- Efimov, V.; Buryakova, A.; Dubey, I.; Polushin, N.; Chakhmakhcheva, O.;
  Ovchinnikov, Y. *Nucleic Acids Res.* 1986, 14, 6526.
- 6. Szabo, T.; Kers, A.; Stawinski, J. Nucleic Acids Res. 1995, 23, 893.
- 7. Varma, R.; Hogan, M. Tetrahedron Lett. 1992, 33, 7719.